Drawing for ACCELERATING MEDICAL INNOVATION

USPTO serial 77600170

ACCELERATING MEDICAL INNOVATION

Reviewed by CopyMark Law Group

Reg. 3825874Status 800Registered
Filing date
Status date
Registration date
Jul 27, 2010
Examiner
GAYNOR, BARBARA ANNE
Law office
GENERIC WEB UPDATE

What this means

Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.

Status 800: Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection.

Need help with ACCELERATING MEDICAL INNOVATION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Robert J. Kenney

Robert J. Kenney WILLCOX & SAVAGE, P.C.8201 Greensboro Drive, Suite 1001Attn.: IP AdministratorMcLean, VA 22102

Goods and services

ClassDescriptionStatusFirst use
035Regulatory submission management, namely, assisting others in preparing Investigational New Drug applications (INDs) and New Drug Applications (NDAs) for submission to the FDA; database managementACTIVEJun 25, 2009
040Consulting services in the field of manufacturing compliance and validation, namely, providing technical advice related to the manufacture of pharmaceuticalsACTIVEJun 25, 2009
042Contract research organization (CRO) services, namely, monitoring of clinical trials for investigational drugs of biotech and pharmaceutical companies, clinical trial project management and quality assurance, medical writing of investigational drug protocols, and medical research in the nature of biostatistical analysis; consulting services in the field of conducting clinical trials, drug development, manufacturing environmental compliance and validation, advanced technology in the pharmaceutical field, and medical research in the nature of clinical benchmarking used to improve the performance of professionals in the fields of international health, the pharmaceutical industry, the biotechnology industry and the medical device and diagnostics industries; providing quality assurance services in the field of regulatory submissions to the FDA by life sciences companies to ensure validity and accuracy; product development for others, namely, providing implementation services relating to the development and validation of drugs, devices and biologicsACTIVEJun 25, 2009
045Legal research, namely, regulatory research in the pharmaceutical industry, biotechnology industry and the medical and diagnostics industry; consultation in the field of regulatory compliance to ensure validity and accuracy of regulatory submissions to the FDA by life sciences companies; conducting regulatory and compliance audits for others, namely, reviewing standards and practices to assure compliance with laws and regulations in the fields of pharmaceutical, veterinary, pharmacogenomic, biotechnical and medical products and devices; providing information relating to legal affairs, namely, providing regulatory information relating to the development and validation of drugs, devices and biologics; regulatory compliance consulting as it applies to clinical trials, namely, monitoring by clinical research administrators for compliance with regulations governing clinical trials; legal document preparation services, namely, preparation of Investigational New Drug applications (INDs) and New Drug Applications (NDAs) for submission to the FDA; consulting services in the field of regulatory affairs and manufacturing compliance and validation, namely, regulatory compliance consulting as it applies to prescription drug sampling; consulting services in the field of clinical benchmarking and performance improvement, namely, providing independent review of clinical trials involving human subjects in the nature of reviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of researchACTIVEJun 25, 2009

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 10, 2025EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Nov 10, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 10, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 10, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 16, 2019NA89NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED—
Nov 16, 2019RNL1REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Nov 16, 201989AGREGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTEDThe USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary.
Nov 16, 2019APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 9, 2019E89RTEAS SECTION 8 & 9 RECEIVED—
Jul 27, 2019REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Jun 20, 2016CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jun 20, 2016COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 19, 2016NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Mar 19, 2016C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Mar 19, 2016APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jan 19, 2016E815TEAS SECTION 8 & 15 RECEIVED—
Jul 27, 2010R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 19, 2010SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jun 18, 2010REGVLAW OFFICE REGISTRATION REVIEW COMPLETED—
Jun 18, 2010ALIEASSIGNED TO LIE—
Jun 3, 2010CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
May 19, 2010DOCKASSIGNED TO EXAMINER—
Apr 26, 2010SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Apr 26, 2010AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 8, 2010IUAFUSE AMENDMENT FILED—
Apr 8, 2010EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Apr 7, 2010ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Apr 6, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 2, 2010EX1GSOU EXTENSION 1 GRANTED—
Apr 2, 2010EXT1SOU EXTENSION 1 FILED—
Apr 2, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 6, 2009NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 14, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 24, 2009NPUBNOTICE OF PUBLICATION—
Jun 8, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 8, 2009ALIEASSIGNED TO LIE—
Jun 5, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 2, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 2, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 2, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 3, 2009GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 3, 2009GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 3, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 27, 2009DOCKASSIGNED TO EXAMINER—
Oct 28, 2008NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance